UBS Group initiated coverage on shares of Waters (NYSE:WAT) in a research report report published on Tuesday, 99wallstreet.com reports. The firm issued a neutral rating and a $210.00 target price on the medical instruments supplier’s stock.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Waters from a hold rating to a buy rating and set a $217.00 price objective for the company in a research report on Saturday, July 7th. Morgan Stanley lowered their price objective on shares of Waters from $205.00 to $204.00 and set an equal weight rating for the company in a research report on Wednesday, July 25th. Leerink Swann lowered shares of Waters from an outperform rating to a market perform rating in a research report on Monday, October 8th. Janney Montgomery Scott lowered shares of Waters from a buy rating to a neutral rating and lowered their price objective for the company from $230.00 to $211.00 in a research report on Tuesday, July 17th. Finally, Robert W. Baird increased their price objective on shares of Waters from $201.00 to $212.00 and gave the company an outperform rating in a research report on Wednesday, July 25th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $208.73.
Shares of NYSE:WAT opened at $181.80 on Tuesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 6.58 and a quick ratio of 5.95. Waters has a fifty-two week low of $177.25 and a fifty-two week high of $220.20. The firm has a market cap of $15.00 billion, a P/E ratio of 24.08, a P/E/G ratio of 2.39 and a beta of 0.93.
In other news, SVP Elizabeth B. Rae sold 4,000 shares of the stock in a transaction on Monday, August 27th. The shares were sold at an average price of $190.62, for a total value of $762,480.00. Following the sale, the senior vice president now owns 9,443 shares of the company’s stock, valued at $1,800,024.66. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.98% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. WP Advisors LLC purchased a new stake in shares of Waters in the second quarter valued at $101,000. Summit Trail Advisors LLC raised its stake in shares of Waters by 68,148.5% in the first quarter. Summit Trail Advisors LLC now owns 113,975 shares of the medical instruments supplier’s stock valued at $114,000 after acquiring an additional 113,808 shares during the period. Fort L.P. purchased a new stake in shares of Waters in the second quarter valued at $118,000. Cornerstone Advisors Inc. raised its stake in shares of Waters by 1,651.2% in the second quarter. Cornerstone Advisors Inc. now owns 753 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 710 shares during the period. Finally, Clinton Group Inc. purchased a new stake in shares of Waters in the third quarter valued at $219,000. 99.31% of the stock is currently owned by institutional investors and hedge funds.
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Featured Story: How is inflation measured?
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.